Akums Drugs & Pharma has made a significant breakthrough in the treatment of Gastroesophageal Reflux Disease (GERD), securing a 20-year patent for its innovative dual release gastro-resistant tablet. This development marks a potential game-changer for millions of GERD patients worldwide.

Patent Details

The company has been granted a patent for an invention entitled "Dual Release Gastro-Resistant Composition" for a term of 20 years, effective from November 19, 2022. This patent, awarded in accordance with the provisions of the Patents Act, 1970, underscores Akums' commitment to advancing pharmaceutical solutions for chronic conditions.

Innovative Technology

The newly patented tablet utilizes a unique tablet-in-tablet technology, designed to provide enhanced relief for GERD patients. Key features of this innovative treatment include:

• Dual Release Mechanism: The tablet releases the medicine in two phases - 50% in the duodenum and 50% in the ileum.
• Extended Absorption: This phased release allows for extended absorption of the drug, resulting in a longer duration of action.
• Once-Daily Dosage: The advanced formulation offers the convenience of a single daily dose.

Addressing a Global Health Concern

GERD is a widespread digestive disorder affecting a significant portion of the global population:

Advantages Over Conventional Treatments

The dual release Proton Pump Inhibitor (PPI) tablet aims to overcome limitations of traditional PPIs:

• Better control over nocturnal acid breakthrough
• More complete symptom relief
• Improved heartburn-free days (daytime and nighttime)
• Enhanced quality of life for patients

Regulatory Approval

This innovative formulation has received approval from the Drug Controller General of India (DCGI), paving the way for its introduction to the market.

Akums Drugs & Pharma's latest innovation represents a significant step forward in GERD treatment, potentially offering improved outcomes for millions of patients struggling with this common digestive disorder. As the company moves forward with this patented technology, it reinforces its position as a key player in developing patient-friendly therapies for chronic acid-related disorders.

Akums Drugs & Pharma has taken a significant step in its international expansion strategy by incorporating a joint venture company in Zambia. The new entity, named Akums Healthcare (Zambia) Private Limited, received its certificate of incorporation on October 13, 2025, marking a pivotal moment in the company's growth trajectory.

Key Details of the Joint Venture

This development follows a series of strategic disclosures made by Akums Drugs & Pharma, indicating a well-planned approach to its international ventures. The company had previously made announcements regarding this initiative on October 18, 2024, and August 22, 2025, showcasing a methodical progression towards establishing its presence in the African pharmaceutical market.

Regulatory Compliance and Transparency

In adherence to regulatory requirements, Akums Drugs & Pharma promptly informed the National Stock Exchange of India Ltd and BSE Limited about this significant corporate action. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparency and regulatory compliance.

Strategic Implications

The establishment of Akums Healthcare (Zambia) Private Limited represents a strategic move by Akums Drugs & Pharma to tap into the growing pharmaceutical market in Africa. This joint venture could potentially:

• Expand the company's geographical footprint
• Provide access to new markets in the African continent
• Leverage local partnerships to navigate the Zambian business landscape
• Introduce the company's pharmaceutical products to a new customer base

While the specific details of the joint venture's operations and ownership structure have not been disclosed, this move signals Akums Drugs & Pharma's intent to diversify its business and explore growth opportunities beyond its home market.

As the pharmaceutical industry continues to evolve globally, such international expansions could play a crucial role in companies' long-term growth strategies. Stakeholders will likely be keen to observe how this joint venture unfolds and contributes to Akums Drugs & Pharma's overall business performance in the coming years.